Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности коррекции железодефицитной анемии у пациентов с патологией пищеварительной системы
Современные возможности коррекции железодефицитной анемии у пациентов с патологией пищеварительной системы
Кудыкин М.Н. Современные возможности коррекции железодефицитной анемии у пациентов с патологией пищеварительной системы. Consilium Medicum. 2017; 19 (7.2. Хирургия): 36–41. DOI: 10.26442/2075-1753_19.7.2.36-41
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Железодефицитная анемия (ЖДА) связана с рядом патологических состояний желудочно-кишечного тракта. Помимо воспалительных заболеваний кишечника ЖДА часто ассоциирована с хроническими заболеваниями печени. Разные факторы, такие как хроническая кровопотеря, мальабсорбция, воспаление, могут способствовать развитию ЖДА. Хотя пациенты с симптомами анемии часто первично обращаются за помощью к гастроэнтерологам, подход к диагностике и лечению, а также меры по последующему контролю за пациентом не являются стандартизированными и оптимальными. Дефицит железа, даже без развития симптомов анемии, может существенно повлиять на состояние физического здоровья и когнитивную функцию, снизить качество жизни. Поэтому важны регулярная оценка концентрации железа и понимание клинических последствий снижения концентрации сывороточного железа также со стороны специалистов другого профиля: хирургов, терапевтов, кардиологов. В настоящее время диапазон вариантов лечения ЖДА увеличивается за счет внедрения в клиническую практику эффективных и хорошо переносимых препаратов железа для парентерального введения. В доступной научной периодике отмечается недостаток систематических обзоров, касающихся лечения ЖДА и, в частности, ее терапии у пациентов с заболеваниями желудочно-кишечного тракта. В представленном обзоре обобщается современное представление о течении ЖДА при специфических желудочно-кишечных и печеночных расстройствах и рассматривается унифицированный подход к лечению анемии и дефицита железа в повседневной клинической практике.
Ключевые слова: железодефицитная анемия, желудочно-кишечные кровотечения, гастрит, бариатрическая хирургия, целиакия, желудочно-кишечные новообразования, хронический гепатит, неалкогольная жировая болезнь печени, цирроз печени.
Key words: iron deficiency anemia, gastrointestinal bleeding, gastritis, bariatric surgery, celiac disease, gastrointestinal neoplasms, chronic hepatitis, nonalcoholic fatty liver disease, cirrhosis of the liver.
Ключевые слова: железодефицитная анемия, желудочно-кишечные кровотечения, гастрит, бариатрическая хирургия, целиакия, желудочно-кишечные новообразования, хронический гепатит, неалкогольная жировая болезнь печени, цирроз печени.
________________________________________________
Key words: iron deficiency anemia, gastrointestinal bleeding, gastritis, bariatric surgery, celiac disease, gastrointestinal neoplasms, chronic hepatitis, nonalcoholic fatty liver disease, cirrhosis of the liver.
Полный текст
Список литературы
1. Gkamprela E, Deutsch M, Pectasides D. Iron deficiency anemia in chronic liver disease: etiopathogenesis, diagnosis and treatment. Ann Gastroenterol 2017; 30 (4): 405–13. DOI: 10.20524/aog.2017.0152
2. Petry N, Olofin I, Hurrell RF, Boy E. The Proportion of Anemia Associated with iron Deficiency in Low, Medium, and High Human Development Index Countries: A Systematic Analysis of National Surveys. Nutrients 2016; 8 (11). pii: E693.
3. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309–16.
4. Marignani M, Angeletti S, Filippi L et al. Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review). Int J Mol Med 2005; 15: 129–35.
5. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010; 16: 2720–5.
6. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci 2010; 55: 548–59.
7. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599–610.
8. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545–53.
9. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211–22.
10. Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage- a placebo-controlled study. Aliment Pharmacol Ther 2014; 39: 176–87.
11. Fernández-Bañares F, Monzón H, Forné M. A short review of malabsorption and anemia. World J Gastroenterol 2009; 15: 4644–52.
12. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009; 15: 4659–65.
13. Niv E, Elis A, Zissin R et al. Iron deficiency anemia in patients without gastrointestinal symptoms – a prospective study. Fam Pract 2005; 22: 58–61.
14. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol 2014; 5: 83.
15. Dharmarajan TS, Bullecer MLF, Pitchumoni CS. Anemia of gastrointestinal origin in the elderly. Pract Gastroenterol 2015; 26: 22–36.
16. Ferguson A, Brydon WG, Brian H et al. Use of whole gut perfusion to investigate gastrointestinal blood loss in patients with iron deficiency anaemia. Gut 1996; 38: 120–4.
17. Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015; 13: 308–18.
18. Geisel T, Martin J, Schulze B et al. An etiologic profile of anemia in 405 geriatric patients. Anemia 2014; 2014: 932486
19. Gomollón F, Gisbert JP, García-Erce JA. Intravenous iron in digestive diseases: a clinical (re)view. Ther Adv Chronic Dis 2010; 1: 67–75.
20. Koch TA, Myers J, Goodnough LT. Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. Anemia 2015; 2015: 763576.
21. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372: 1832–43.
22. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387: 907–16.
23. Carrott PW, Markar SR, Hong J et al. Iron-deficiency anemia is a common presenting issue with giant paraesophageal hernia and resolves following repair. J Gastrointest Surg 2013; 17: 858–62.
24. Panzuto F, Di Giulio E, Capurso G et al. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. Aliment Pharmacol Ther 2004; 19: 663–70.
25. Ruhl CE, Everhart JE. Relationship of iron-deficiency anemia with esophagitis and hiatal hernia: hospital findings from a prospective, population-based study. Am J Gastroenterol 2001; 96: 322–6.
26. Crooks CJ, West J, Card TR. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2012; 61: 514–20.
27. Barkun AN, Bardou M, Kuipers et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101–13.
28. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002; 51 (Suppl. 4): iv1–iv6.
29. Bager P, Dahlerup JF. Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre. Dan Med J 2013; 60: A4583.
30. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–21.
31. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134–41.
32. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9.
33. Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751–67.
34. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55–9.
35. Maiden L, Thjodleifsson B, Theodors A et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172–8.
36. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008; 10: R7.
37. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8.
38. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624.
39. Toyoda H, Tanabe N, Toyoda M et al. Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers. Clin J Gastroenterol 2012; 5: 155–7.
40. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–41.
41. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131–7.
42. Nguyen H, Le C, Nguyen H. Gastric antral vascular ectasia (watermelon stomach)-an enigmatic and often-overlooked cause of gastrointestinal bleeding in the elderly. Perm J 2009; 13: 46–9.
43. Johnson J, Derk CT. Gastric antral vascular ectasia in systemic sclerosis. Int J Rheumatol 2011; 2011: 305238.
44. Ghrénassia E, Avouac J, Khanna D et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014; 41: 99–105.
45. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010; 14: 281–95.
46. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014; 123: 326–33.
47. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013; 10: 529–41.
48. Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr 2015; 102: 9–19.
49. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol 2014; 11: 234–42.
50. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323–40.
51. Yuan W, Li Yumin D, Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
52. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
53. Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1–20.
54. Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline “helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230–63.
55. Fock KM, Talley N, Moayyedi P et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351–65.
56. Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40: 582–609.
57. Aills L, Blankenship J, Buffington C et al. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis 2008; 4: S73–108.
58. Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol 2008; 83: 403–9.
59 Ten Broeke R, Bravenboer B, Smulders FJ. Iron deficiency before and after bariatric surgery: the need for iron supplementation. Neth J Med 2013; 71: 412–7.
60. Obinwanne KM, Fredrickson KA, Mathiason MA et al. Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis. J Am Coll Surg 2014; 218: 246–52.
61. Apovian CM, Cummings S, Anderson W et al. Best practice updates for multidisciplinary care in weight loss surgery. Obesity (Silver Spring) 2009; 17: 871–9.
62. Godfrey JD, Brantner TL, Brinjikji W et al. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010; 139: 763–9.
63 Çekın AH, Çekın Y, Sezer C. Celiac disease prevalence in patients with iron deficiency anemia. Turk J Gastroenterol 2012; 23: 490–5.
64. Unsworth DJ, Lock FJ, Harvey RF. Iron-deficiency anaemia in premenopausal women. Lancet 1999; 353: 1100.
65. Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998–2012) in an Italian referral center. BMC Gastroenterol 2014; 14: 194.
66. Wierdsma NJ, van Bokhorst-de van der Schueren MA, Berkenpas M et al. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Nutrients 2013; 5: 3975–92.
67. Hershko C, Patz J. Ironing out the mechanism of anemia in celiac disease. Haematologica 2008; 93: 1761–5.
68. Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996; 334: 1163–7.
69. Harper JW, Holleran SF, Ramakrishnan R et al. Anemia in celiac disease is multifactorial in etiology. Am J Hematol 2007; 82: 996–1000.
70. Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol 2005; 78: 261–4.
71. Annibale B, Severi C, Chistolini A et al. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. Am J Gastroenterol 2001; 96: 132–7.
72. Pironi L, Arends J, Baxter J et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015; 34: 171–80.
73. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130: 70–7.
74. Hwa YL, Rashtak S, Kelly DG, Murray JA. Iron Deficiency in Long-Term Parenteral Nutrition Therapy. JPEN J Parenter Enteral Nutr 2016; 40: 869–76.
75. Ranganathan P, Pramesh CS. Letter 1: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2010; 97: 297–8.
76. World Gastroenterology Organisation. World Gastroenterology Organisation Practice Guidelines: Diverticular Disease.
77. Kubo A, Kagaya T, Nakagawa H. Studies on complications of diverticular disease of the colon. Jpn J Med 1985; 24: 39–43.
78. Siddique A, Nelson JE, Aouizerat B et al. Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol 2014; 12: 1170–8.
79. Ruivard M, Lainé F, Ganz T et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219–25.
80. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61: 933–52.
81. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844–51.
82. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12–33.
83. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13–22.
84. Jumaa AK. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; (Suppl. 2): 279–335.
85. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–847.
86. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399–412.
87. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–82.
88. Yessayan L, Sandhu A, Besarab A et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol 2013; 2013: 703038.
89. European Medicines Agency (EMA) Assessment report for: Iron containing intravenous (IV) medicinal products.
90. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182–92.
91. Erichsen K, Ulvik RJ, Nysaeter G et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058–65.
92. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel diseaseea randomized, controlled, openlabel, multicenter study. Am J Gastroenterol 2005; 100: 2503–9.
93. Evstatiev R, Marteau F, Iqbal T et al. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology 2011; 141: 846–53.
94. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267–78.
95. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719–28.
96. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010; 60: 386–98.
2. Petry N, Olofin I, Hurrell RF, Boy E. The Proportion of Anemia Associated with iron Deficiency in Low, Medium, and High Human Development Index Countries: A Systematic Analysis of National Surveys. Nutrients 2016; 8 (11). pii: E693.
3. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309–16.
4. Marignani M, Angeletti S, Filippi L et al. Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review). Int J Mol Med 2005; 15: 129–35.
5. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010; 16: 2720–5.
6. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci 2010; 55: 548–59.
7. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599–610.
8. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545–53.
9. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211–22.
10. Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage- a placebo-controlled study. Aliment Pharmacol Ther 2014; 39: 176–87.
11. Fernández-Bañares F, Monzón H, Forné M. A short review of malabsorption and anemia. World J Gastroenterol 2009; 15: 4644–52.
12. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009; 15: 4659–65.
13. Niv E, Elis A, Zissin R et al. Iron deficiency anemia in patients without gastrointestinal symptoms – a prospective study. Fam Pract 2005; 22: 58–61.
14. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol 2014; 5: 83.
15. Dharmarajan TS, Bullecer MLF, Pitchumoni CS. Anemia of gastrointestinal origin in the elderly. Pract Gastroenterol 2015; 26: 22–36.
16. Ferguson A, Brydon WG, Brian H et al. Use of whole gut perfusion to investigate gastrointestinal blood loss in patients with iron deficiency anaemia. Gut 1996; 38: 120–4.
17. Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015; 13: 308–18.
18. Geisel T, Martin J, Schulze B et al. An etiologic profile of anemia in 405 geriatric patients. Anemia 2014; 2014: 932486
19. Gomollón F, Gisbert JP, García-Erce JA. Intravenous iron in digestive diseases: a clinical (re)view. Ther Adv Chronic Dis 2010; 1: 67–75.
20. Koch TA, Myers J, Goodnough LT. Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. Anemia 2015; 2015: 763576.
21. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372: 1832–43.
22. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387: 907–16.
23. Carrott PW, Markar SR, Hong J et al. Iron-deficiency anemia is a common presenting issue with giant paraesophageal hernia and resolves following repair. J Gastrointest Surg 2013; 17: 858–62.
24. Panzuto F, Di Giulio E, Capurso G et al. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. Aliment Pharmacol Ther 2004; 19: 663–70.
25. Ruhl CE, Everhart JE. Relationship of iron-deficiency anemia with esophagitis and hiatal hernia: hospital findings from a prospective, population-based study. Am J Gastroenterol 2001; 96: 322–6.
26. Crooks CJ, West J, Card TR. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2012; 61: 514–20.
27. Barkun AN, Bardou M, Kuipers et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101–13.
28. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002; 51 (Suppl. 4): iv1–iv6.
29. Bager P, Dahlerup JF. Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre. Dan Med J 2013; 60: A4583.
30. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–21.
31. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134–41.
32. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9.
33. Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751–67.
34. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55–9.
35. Maiden L, Thjodleifsson B, Theodors A et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172–8.
36. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008; 10: R7.
37. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8.
38. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624.
39. Toyoda H, Tanabe N, Toyoda M et al. Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers. Clin J Gastroenterol 2012; 5: 155–7.
40. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–41.
41. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131–7.
42. Nguyen H, Le C, Nguyen H. Gastric antral vascular ectasia (watermelon stomach)-an enigmatic and often-overlooked cause of gastrointestinal bleeding in the elderly. Perm J 2009; 13: 46–9.
43. Johnson J, Derk CT. Gastric antral vascular ectasia in systemic sclerosis. Int J Rheumatol 2011; 2011: 305238.
44. Ghrénassia E, Avouac J, Khanna D et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014; 41: 99–105.
45. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010; 14: 281–95.
46. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014; 123: 326–33.
47. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013; 10: 529–41.
48. Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr 2015; 102: 9–19.
49. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol 2014; 11: 234–42.
50. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323–40.
51. Yuan W, Li Yumin D, Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
52. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
53. Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1–20.
54. Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline “helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230–63.
55. Fock KM, Talley N, Moayyedi P et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351–65.
56. Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40: 582–609.
57. Aills L, Blankenship J, Buffington C et al. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis 2008; 4: S73–108.
58. Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol 2008; 83: 403–9.
59 Ten Broeke R, Bravenboer B, Smulders FJ. Iron deficiency before and after bariatric surgery: the need for iron supplementation. Neth J Med 2013; 71: 412–7.
60. Obinwanne KM, Fredrickson KA, Mathiason MA et al. Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis. J Am Coll Surg 2014; 218: 246–52.
61. Apovian CM, Cummings S, Anderson W et al. Best practice updates for multidisciplinary care in weight loss surgery. Obesity (Silver Spring) 2009; 17: 871–9.
62. Godfrey JD, Brantner TL, Brinjikji W et al. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010; 139: 763–9.
63 Çekın AH, Çekın Y, Sezer C. Celiac disease prevalence in patients with iron deficiency anemia. Turk J Gastroenterol 2012; 23: 490–5.
64. Unsworth DJ, Lock FJ, Harvey RF. Iron-deficiency anaemia in premenopausal women. Lancet 1999; 353: 1100.
65. Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998–2012) in an Italian referral center. BMC Gastroenterol 2014; 14: 194.
66. Wierdsma NJ, van Bokhorst-de van der Schueren MA, Berkenpas M et al. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Nutrients 2013; 5: 3975–92.
67. Hershko C, Patz J. Ironing out the mechanism of anemia in celiac disease. Haematologica 2008; 93: 1761–5.
68. Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996; 334: 1163–7.
69. Harper JW, Holleran SF, Ramakrishnan R et al. Anemia in celiac disease is multifactorial in etiology. Am J Hematol 2007; 82: 996–1000.
70. Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol 2005; 78: 261–4.
71. Annibale B, Severi C, Chistolini A et al. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. Am J Gastroenterol 2001; 96: 132–7.
72. Pironi L, Arends J, Baxter J et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015; 34: 171–80.
73. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130: 70–7.
74. Hwa YL, Rashtak S, Kelly DG, Murray JA. Iron Deficiency in Long-Term Parenteral Nutrition Therapy. JPEN J Parenter Enteral Nutr 2016; 40: 869–76.
75. Ranganathan P, Pramesh CS. Letter 1: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2010; 97: 297–8.
76. World Gastroenterology Organisation. World Gastroenterology Organisation Practice Guidelines: Diverticular Disease.
77. Kubo A, Kagaya T, Nakagawa H. Studies on complications of diverticular disease of the colon. Jpn J Med 1985; 24: 39–43.
78. Siddique A, Nelson JE, Aouizerat B et al. Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol 2014; 12: 1170–8.
79. Ruivard M, Lainé F, Ganz T et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219–25.
80. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61: 933–52.
81. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844–51.
82. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12–33.
83. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13–22.
84. Jumaa AK. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; (Suppl. 2): 279–335.
85. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–847.
86. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399–412.
87. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–82.
88. Yessayan L, Sandhu A, Besarab A et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol 2013; 2013: 703038.
89. European Medicines Agency (EMA) Assessment report for: Iron containing intravenous (IV) medicinal products.
90. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182–92.
91. Erichsen K, Ulvik RJ, Nysaeter G et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058–65.
92. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel diseaseea randomized, controlled, openlabel, multicenter study. Am J Gastroenterol 2005; 100: 2503–9.
93. Evstatiev R, Marteau F, Iqbal T et al. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology 2011; 141: 846–53.
94. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267–78.
95. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719–28.
96. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010; 60: 386–98.
2. Petry N, Olofin I, Hurrell RF, Boy E. The Proportion of Anemia Associated with iron Deficiency in Low, Medium, and High Human Development Index Countries: A Systematic Analysis of National Surveys. Nutrients 2016; 8 (11). pii: E693.
3. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309–16.
4. Marignani M, Angeletti S, Filippi L et al. Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review). Int J Mol Med 2005; 15: 129–35.
5. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010; 16: 2720–5.
6. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci 2010; 55: 548–59.
7. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599–610.
8. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545–53.
9. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211–22.
10. Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage- a placebo-controlled study. Aliment Pharmacol Ther 2014; 39: 176–87.
11. Fernández-Bañares F, Monzón H, Forné M. A short review of malabsorption and anemia. World J Gastroenterol 2009; 15: 4644–52.
12. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009; 15: 4659–65.
13. Niv E, Elis A, Zissin R et al. Iron deficiency anemia in patients without gastrointestinal symptoms – a prospective study. Fam Pract 2005; 22: 58–61.
14. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol 2014; 5: 83.
15. Dharmarajan TS, Bullecer MLF, Pitchumoni CS. Anemia of gastrointestinal origin in the elderly. Pract Gastroenterol 2015; 26: 22–36.
16. Ferguson A, Brydon WG, Brian H et al. Use of whole gut perfusion to investigate gastrointestinal blood loss in patients with iron deficiency anaemia. Gut 1996; 38: 120–4.
17. Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015; 13: 308–18.
18. Geisel T, Martin J, Schulze B et al. An etiologic profile of anemia in 405 geriatric patients. Anemia 2014; 2014: 932486
19. Gomollón F, Gisbert JP, García-Erce JA. Intravenous iron in digestive diseases: a clinical (re)view. Ther Adv Chronic Dis 2010; 1: 67–75.
20. Koch TA, Myers J, Goodnough LT. Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. Anemia 2015; 2015: 763576.
21. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372: 1832–43.
22. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387: 907–16.
23. Carrott PW, Markar SR, Hong J et al. Iron-deficiency anemia is a common presenting issue with giant paraesophageal hernia and resolves following repair. J Gastrointest Surg 2013; 17: 858–62.
24. Panzuto F, Di Giulio E, Capurso G et al. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. Aliment Pharmacol Ther 2004; 19: 663–70.
25. Ruhl CE, Everhart JE. Relationship of iron-deficiency anemia with esophagitis and hiatal hernia: hospital findings from a prospective, population-based study. Am J Gastroenterol 2001; 96: 322–6.
26. Crooks CJ, West J, Card TR. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2012; 61: 514–20.
27. Barkun AN, Bardou M, Kuipers et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101–13.
28. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002; 51 (Suppl. 4): iv1–iv6.
29. Bager P, Dahlerup JF. Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre. Dan Med J 2013; 60: A4583.
30. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–21.
31. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134–41.
32. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9.
33. Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751–67.
34. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55–9.
35. Maiden L, Thjodleifsson B, Theodors A et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172–8.
36. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008; 10: R7.
37. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8.
38. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624.
39. Toyoda H, Tanabe N, Toyoda M et al. Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers. Clin J Gastroenterol 2012; 5: 155–7.
40. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–41.
41. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131–7.
42. Nguyen H, Le C, Nguyen H. Gastric antral vascular ectasia (watermelon stomach)-an enigmatic and often-overlooked cause of gastrointestinal bleeding in the elderly. Perm J 2009; 13: 46–9.
43. Johnson J, Derk CT. Gastric antral vascular ectasia in systemic sclerosis. Int J Rheumatol 2011; 2011: 305238.
44. Ghrénassia E, Avouac J, Khanna D et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014; 41: 99–105.
45. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010; 14: 281–95.
46. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014; 123: 326–33.
47. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013; 10: 529–41.
48. Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr 2015; 102: 9–19.
49. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol 2014; 11: 234–42.
50. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323–40.
51. Yuan W, Li Yumin D, Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
52. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
53. Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1–20.
54. Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline “helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230–63.
55. Fock KM, Talley N, Moayyedi P et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351–65.
56. Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40: 582–609.
57. Aills L, Blankenship J, Buffington C et al. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis 2008; 4: S73–108.
58. Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol 2008; 83: 403–9.
59 Ten Broeke R, Bravenboer B, Smulders FJ. Iron deficiency before and after bariatric surgery: the need for iron supplementation. Neth J Med 2013; 71: 412–7.
60. Obinwanne KM, Fredrickson KA, Mathiason MA et al. Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis. J Am Coll Surg 2014; 218: 246–52.
61. Apovian CM, Cummings S, Anderson W et al. Best practice updates for multidisciplinary care in weight loss surgery. Obesity (Silver Spring) 2009; 17: 871–9.
62. Godfrey JD, Brantner TL, Brinjikji W et al. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010; 139: 763–9.
63 Çekın AH, Çekın Y, Sezer C. Celiac disease prevalence in patients with iron deficiency anemia. Turk J Gastroenterol 2012; 23: 490–5.
64. Unsworth DJ, Lock FJ, Harvey RF. Iron-deficiency anaemia in premenopausal women. Lancet 1999; 353: 1100.
65. Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998–2012) in an Italian referral center. BMC Gastroenterol 2014; 14: 194.
66. Wierdsma NJ, van Bokhorst-de van der Schueren MA, Berkenpas M et al. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Nutrients 2013; 5: 3975–92.
67. Hershko C, Patz J. Ironing out the mechanism of anemia in celiac disease. Haematologica 2008; 93: 1761–5.
68. Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996; 334: 1163–7.
69. Harper JW, Holleran SF, Ramakrishnan R et al. Anemia in celiac disease is multifactorial in etiology. Am J Hematol 2007; 82: 996–1000.
70. Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol 2005; 78: 261–4.
71. Annibale B, Severi C, Chistolini A et al. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. Am J Gastroenterol 2001; 96: 132–7.
72. Pironi L, Arends J, Baxter J et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015; 34: 171–80.
73. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130: 70–7.
74. Hwa YL, Rashtak S, Kelly DG, Murray JA. Iron Deficiency in Long-Term Parenteral Nutrition Therapy. JPEN J Parenter Enteral Nutr 2016; 40: 869–76.
75. Ranganathan P, Pramesh CS. Letter 1: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2010; 97: 297–8.
76. World Gastroenterology Organisation. World Gastroenterology Organisation Practice Guidelines: Diverticular Disease.
77. Kubo A, Kagaya T, Nakagawa H. Studies on complications of diverticular disease of the colon. Jpn J Med 1985; 24: 39–43.
78. Siddique A, Nelson JE, Aouizerat B et al. Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol 2014; 12: 1170–8.
79. Ruivard M, Lainé F, Ganz T et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219–25.
80. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61: 933–52.
81. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844–51.
82. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12–33.
83. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13–22.
84. Jumaa AK. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; (Suppl. 2): 279–335.
85. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–847.
86. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399–412.
87. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–82.
88. Yessayan L, Sandhu A, Besarab A et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol 2013; 2013: 703038.
89. European Medicines Agency (EMA) Assessment report for: Iron containing intravenous (IV) medicinal products.
90. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182–92.
91. Erichsen K, Ulvik RJ, Nysaeter G et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058–65.
92. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel diseaseea randomized, controlled, openlabel, multicenter study. Am J Gastroenterol 2005; 100: 2503–9.
93. Evstatiev R, Marteau F, Iqbal T et al. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology 2011; 141: 846–53.
94. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267–78.
95. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719–28.
96. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010; 60: 386–98.
________________________________________________
2. Petry N, Olofin I, Hurrell RF, Boy E. The Proportion of Anemia Associated with iron Deficiency in Low, Medium, and High Human Development Index Countries: A Systematic Analysis of National Surveys. Nutrients 2016; 8 (11). pii: E693.
3. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309–16.
4. Marignani M, Angeletti S, Filippi L et al. Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review). Int J Mol Med 2005; 15: 129–35.
5. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010; 16: 2720–5.
6. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci 2010; 55: 548–59.
7. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599–610.
8. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545–53.
9. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211–22.
10. Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage- a placebo-controlled study. Aliment Pharmacol Ther 2014; 39: 176–87.
11. Fernández-Bañares F, Monzón H, Forné M. A short review of malabsorption and anemia. World J Gastroenterol 2009; 15: 4644–52.
12. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009; 15: 4659–65.
13. Niv E, Elis A, Zissin R et al. Iron deficiency anemia in patients without gastrointestinal symptoms – a prospective study. Fam Pract 2005; 22: 58–61.
14. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol 2014; 5: 83.
15. Dharmarajan TS, Bullecer MLF, Pitchumoni CS. Anemia of gastrointestinal origin in the elderly. Pract Gastroenterol 2015; 26: 22–36.
16. Ferguson A, Brydon WG, Brian H et al. Use of whole gut perfusion to investigate gastrointestinal blood loss in patients with iron deficiency anaemia. Gut 1996; 38: 120–4.
17. Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015; 13: 308–18.
18. Geisel T, Martin J, Schulze B et al. An etiologic profile of anemia in 405 geriatric patients. Anemia 2014; 2014: 932486
19. Gomollón F, Gisbert JP, García-Erce JA. Intravenous iron in digestive diseases: a clinical (re)view. Ther Adv Chronic Dis 2010; 1: 67–75.
20. Koch TA, Myers J, Goodnough LT. Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. Anemia 2015; 2015: 763576.
21. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372: 1832–43.
22. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387: 907–16.
23. Carrott PW, Markar SR, Hong J et al. Iron-deficiency anemia is a common presenting issue with giant paraesophageal hernia and resolves following repair. J Gastrointest Surg 2013; 17: 858–62.
24. Panzuto F, Di Giulio E, Capurso G et al. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. Aliment Pharmacol Ther 2004; 19: 663–70.
25. Ruhl CE, Everhart JE. Relationship of iron-deficiency anemia with esophagitis and hiatal hernia: hospital findings from a prospective, population-based study. Am J Gastroenterol 2001; 96: 322–6.
26. Crooks CJ, West J, Card TR. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2012; 61: 514–20.
27. Barkun AN, Bardou M, Kuipers et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101–13.
28. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002; 51 (Suppl. 4): iv1–iv6.
29. Bager P, Dahlerup JF. Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre. Dan Med J 2013; 60: A4583.
30. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–21.
31. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134–41.
32. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9.
33. Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751–67.
34. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55–9.
35. Maiden L, Thjodleifsson B, Theodors A et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172–8.
36. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008; 10: R7.
37. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8.
38. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624.
39. Toyoda H, Tanabe N, Toyoda M et al. Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers. Clin J Gastroenterol 2012; 5: 155–7.
40. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–41.
41. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131–7.
42. Nguyen H, Le C, Nguyen H. Gastric antral vascular ectasia (watermelon stomach)-an enigmatic and often-overlooked cause of gastrointestinal bleeding in the elderly. Perm J 2009; 13: 46–9.
43. Johnson J, Derk CT. Gastric antral vascular ectasia in systemic sclerosis. Int J Rheumatol 2011; 2011: 305238.
44. Ghrénassia E, Avouac J, Khanna D et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014; 41: 99–105.
45. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010; 14: 281–95.
46. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014; 123: 326–33.
47. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013; 10: 529–41.
48. Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr 2015; 102: 9–19.
49. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol 2014; 11: 234–42.
50. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323–40.
51. Yuan W, Li Yumin D, Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
52. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
53. Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1–20.
54. Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline “helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230–63.
55. Fock KM, Talley N, Moayyedi P et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351–65.
56. Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40: 582–609.
57. Aills L, Blankenship J, Buffington C et al. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis 2008; 4: S73–108.
58. Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol 2008; 83: 403–9.
59 Ten Broeke R, Bravenboer B, Smulders FJ. Iron deficiency before and after bariatric surgery: the need for iron supplementation. Neth J Med 2013; 71: 412–7.
60. Obinwanne KM, Fredrickson KA, Mathiason MA et al. Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis. J Am Coll Surg 2014; 218: 246–52.
61. Apovian CM, Cummings S, Anderson W et al. Best practice updates for multidisciplinary care in weight loss surgery. Obesity (Silver Spring) 2009; 17: 871–9.
62. Godfrey JD, Brantner TL, Brinjikji W et al. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010; 139: 763–9.
63 Çekın AH, Çekın Y, Sezer C. Celiac disease prevalence in patients with iron deficiency anemia. Turk J Gastroenterol 2012; 23: 490–5.
64. Unsworth DJ, Lock FJ, Harvey RF. Iron-deficiency anaemia in premenopausal women. Lancet 1999; 353: 1100.
65. Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998–2012) in an Italian referral center. BMC Gastroenterol 2014; 14: 194.
66. Wierdsma NJ, van Bokhorst-de van der Schueren MA, Berkenpas M et al. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Nutrients 2013; 5: 3975–92.
67. Hershko C, Patz J. Ironing out the mechanism of anemia in celiac disease. Haematologica 2008; 93: 1761–5.
68. Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996; 334: 1163–7.
69. Harper JW, Holleran SF, Ramakrishnan R et al. Anemia in celiac disease is multifactorial in etiology. Am J Hematol 2007; 82: 996–1000.
70. Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol 2005; 78: 261–4.
71. Annibale B, Severi C, Chistolini A et al. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. Am J Gastroenterol 2001; 96: 132–7.
72. Pironi L, Arends J, Baxter J et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015; 34: 171–80.
73. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130: 70–7.
74. Hwa YL, Rashtak S, Kelly DG, Murray JA. Iron Deficiency in Long-Term Parenteral Nutrition Therapy. JPEN J Parenter Enteral Nutr 2016; 40: 869–76.
75. Ranganathan P, Pramesh CS. Letter 1: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2010; 97: 297–8.
76. World Gastroenterology Organisation. World Gastroenterology Organisation Practice Guidelines: Diverticular Disease.
77. Kubo A, Kagaya T, Nakagawa H. Studies on complications of diverticular disease of the colon. Jpn J Med 1985; 24: 39–43.
78. Siddique A, Nelson JE, Aouizerat B et al. Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol 2014; 12: 1170–8.
79. Ruivard M, Lainé F, Ganz T et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219–25.
80. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61: 933–52.
81. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844–51.
82. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12–33.
83. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13–22.
84. Jumaa AK. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; (Suppl. 2): 279–335.
85. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–847.
86. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399–412.
87. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–82.
88. Yessayan L, Sandhu A, Besarab A et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol 2013; 2013: 703038.
89. European Medicines Agency (EMA) Assessment report for: Iron containing intravenous (IV) medicinal products.
90. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182–92.
91. Erichsen K, Ulvik RJ, Nysaeter G et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058–65.
92. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel diseaseea randomized, controlled, openlabel, multicenter study. Am J Gastroenterol 2005; 100: 2503–9.
93. Evstatiev R, Marteau F, Iqbal T et al. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology 2011; 141: 846–53.
94. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267–78.
95. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719–28.
96. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010; 60: 386–98.
Авторы
М.Н.Кудыкин*
ФГБУ «Приволжский федеральный медицинский исследовательский центр» Минздрава России. 603155, Россия, Нижний Новгород,
Верхне-Волжская наб., д. 18
*mady5@yandex.ru
Volga Region Federal Medical Research Center of the Ministry of Health of the Russian Federation. 603155, Russian Federation, Nizhny Novgorod,
Verkhne-Volzhskaia nab., d. 18
*mady5@yandex.ru
ФГБУ «Приволжский федеральный медицинский исследовательский центр» Минздрава России. 603155, Россия, Нижний Новгород,
Верхне-Волжская наб., д. 18
*mady5@yandex.ru
________________________________________________
Volga Region Federal Medical Research Center of the Ministry of Health of the Russian Federation. 603155, Russian Federation, Nizhny Novgorod,
Verkhne-Volzhskaia nab., d. 18
*mady5@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.